World Health Organization Sounds Alert Over Critical Scarcity of Obesity Jabs

Under a tenth of patients that would benefit from weight-loss injections like Wegovy are able to get them, caution the WHO as it issues its initial recommendations on the therapies.

With in excess of 1,000,000,000 individuals worldwide now living with obesity, it is urging more widespread and fairer access to GLP-1 medication.

Based on projections, more than two billion will be obese by 2030 if no action is taken.

"The latest guidance affirms that excess weight is a lifelong illness that can be managed with thorough and ongoing treatment," stated the agency's head Tedros Adhanom Ghebreyesus.

Substantial prices, constrained manufacturing, and logistical bottlenecks are significant obstacles to broad availability to the treatments that can aid individuals in losing significant weight, says the body.

GLP-1 Therapy Supply Crisis

Even under the present best projected outlook, the production of these medications might only reach about 100 million people – under 10% of eligible patients, as stated by the WHO.

The guideline encourages countries and companies to increase availability, via measures like patent sharing.

Exclusive production rights on semaglutide – the core component of Novo Nordisk's Wegovy – is scheduled to end in several nations in 2026.

How Obesity Jabs Function

These medications imitate a natural hormone to slow digestion, reduce hunger and enhance feelings of fullness so people consume fewer calories.

Individuals typically begin shedding pounds within a few weeks of beginning the weekly injections.

Studies points to users may see weight return within a year of stopping the drug, as their usual food cravings come back.

To be above a healthy weight elevates your risk for contracting diseases, including type 2 diabetes, heart disease, brain attack, and certain cancers.

Obesity impacts individuals in every country and was responsible for millions of fatalities worldwide in 2024, according to the WHO.